Affy Hopes Rx-Development Apps, New Platform Will Drive Growth After 'Tough' 2008

Affy aims to target downstream genomic-analysis markets with the products gained through its acquisitions of Panomics and True Materials last year, roll out new genotyping assays on its GeneTitan array platform, and consolidate its manufacturing facilities.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.